Quantcast
Last updated on April 18, 2014 at 1:21 EDT

MMG CEO John Benbrook Named to Board of Advisors for Center for Information and Study on Clinical Research Participation (CISCRP)

March 15, 2011

ROCKVILLE, Md., March 15, 2011 /PRNewswire/ — MMG (www.wegetpatients.com), a full-service patient recruitment and retention group, today announces the appointment of CEO John Benbrook to the board of advisors for the Center for Information and Study on Clinical Research Participation (CISCRP).

“We’re delighted to have John join CISCRP’s board of advisors,” said Diane Simmons, president and CEO, CISCRP. “Over the past several years, John has volunteered his time on CISCRP committees, during which he has demonstrated his commitment to the organization’s mission. We believe John’s advice and guidance will help CISCRP further advance our goals.”

Founded in 2003, CISCRP is a first-of-its-kind nonprofit organization dedicated to educating and informing the public, patients, medical and research professionals, the media, and policymakers about clinical research participation and the role that each party plays as a participant in the process.

“I am honored to join Diane, Ken Getz, and their strong team of dedicated colleagues,” Benbrook said. “The CISCRP team has done a tremendous job of building support and momentum for this important effort, and I look forward to increasing my role in the organization’s efforts to serve patients and our industry.”

Benbrook has more than 20 years of experience in healthcare, pharmaceutical and life science organizations. He joined MMG as vice president in 2004 and became CEO in 2006. Later that year, he was named one of PharmaVOICE‘s 100 Most Inspiring People in the Life-Sciences Industry. In 2009, Benbrook was named a partner at MMG’s parent company Ketchum, a leading global communications consultancy.

About MMG

MMG, a Ketchum company and part of the Omnicom Group (NYSE: OMC) family, is the premier global patient recruitment and retention organization. With experience across a vast range of therapeutic areas, populations, and study types in more than 70 countries, MMG provides strategies that will be accepted by study teams, ethics committees and patient populations while delivering the best return on investment for the sponsor.

SOURCE MMG; Ketchum


Source: newswire